256 related articles for article (PubMed ID: 21536864)
1. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Hasford J; Baccarani M; Hoffmann V; Guilhot J; Saussele S; Rosti G; Guilhot F; Porkka K; Ossenkoppele G; Lindoerfer D; Simonsson B; Pfirrmann M; Hehlmann R
Blood; 2011 Jul; 118(3):686-92. PubMed ID: 21536864
[TBL] [Abstract][Full Text] [Related]
2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
3. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
4. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
[TBL] [Abstract][Full Text] [Related]
5. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G;
Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938
[TBL] [Abstract][Full Text] [Related]
6. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.
Yahng SA; Jang EJ; Choi SY; Lee SE; Kim SH; Kim DW
Int J Hematol; 2014 Aug; 100(2):132-40. PubMed ID: 24879034
[TBL] [Abstract][Full Text] [Related]
7. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
8. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
10. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Huntly BJ; Guilhot F; Reid AG; Vassiliou G; Hennig E; Franke C; Byrne J; Brizard A; Niederwieser D; Freeman-Edward J; Cuthbert G; Bown N; Clark RE; Nacheva EP; Green AR; Deininger MW
Blood; 2003 Sep; 102(6):2205-12. PubMed ID: 12750153
[TBL] [Abstract][Full Text] [Related]
11. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
Yamamoto E; Fujisawa S; Hagihara M; Tanaka M; Fujimaki K; Kishimoto K; Hashimoto C; Itabashi M; Ishibashi D; Nakajima Y; Tachibana T; Kawasaki R; Kuwabara H; Koharazawa H; Yamazaki E; Tomita N; Sakai R; Fujita H; Kanamori H; Ishigatsubo Y
Cancer Sci; 2014 Jan; 105(1):105-9. PubMed ID: 24450386
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.
Liu YC; Hsiao HH; Chang JG; Yang MY; Liu TC; Chang CS; Tseng SB; Tsai HJ; Lin SF
Int J Hematol; 2006 Dec; 84(5):425-31. PubMed ID: 17189224
[TBL] [Abstract][Full Text] [Related]
14. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Baccarani M; Rosti G; Castagnetti F; Haznedaroglu I; Porkka K; Abruzzese E; Alimena G; Ehrencrona H; Hjorth-Hansen H; Kairisto V; Levato L; Martinelli G; Nagler A; Lanng Nielsen J; Ozbek U; Palandri F; Palmieri F; Pane F; Rege-Cambrin G; Russo D; Specchia G; Testoni N; Weiss-Bjerrum O; Saglio G; Simonsson B
Blood; 2009 May; 113(19):4497-504. PubMed ID: 19264678
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
[TBL] [Abstract][Full Text] [Related]
16. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
[TBL] [Abstract][Full Text] [Related]
17. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
18. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
20. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
